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ABSTRACT 
Characterisation of G protein-coupled receptors (GPCR) relies on the availability of a toolbox of 
ligands that selectively modulate different functional states of the receptors. To uncover such 
molecules, we explored a unique strategy for ligand discovery that takes advantage of the 
evolutionary conservation of the 600-million-year-old oxytocin/vasopressin signalling system. We 
isolated the insect oxytocin/vasopressin orthologue inotocin from the black garden ant (Lasius 
niger), identified and cloned its cognate receptor and determined its pharmacological properties on 
the insect and human oxytocin/vasopressin receptors. Subsequently, we identified a functional 
dichotomy: inotocin activated the insect inotocin and the human vasopressin V1b receptors, but 
inhibited the human V1aR. Replacement of Arg8 of inotocin by D-Arg8 led to a potent, stable and 
competitive V1aR-antagonist ([D-Arg8]-inotocin) with a 3,000-fold binding selectivity for the human 
V1aR over the other three subtypes, OTR, V1bR and V2R. The Arg8/D-Arg8 ligand-pair was further 
investigated to gain novel insights into the oxytocin/vasopressin peptide-receptor interaction, which 
led to the identification of key residues of the receptors that are important for ligand functionality 
and selectivity. These observations could play an important role for development of 
oxytocin/vasopressin receptor modulators that would enable clear distinction of the physiological 
and pathological responses of the individual receptor subtypes.   
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INTRODUCTION 
G protein-coupled receptors (GPCRs) represent one of the largest families of membrane bound 
proteins in the human genome1,2. They form attractive drug targets as they play a crucial role in the 
regulation of physiological signalling systems and are accessible at the cell surface3. In recent 
years, the field of GPCR research has evolved at great pace; advances in structural 
characterisation of several GPCRs has led to detailed analyses of their pharmacological 
properties4,5. Such studies rely heavily on the availability of a chemical toolbox of compounds6 that 
selectively stabilize conformational states of GPCRs. The alliance between chemistry and 
pharmacology has led to astonishing breakthroughs in understanding ligand-receptor interactions 
and the development of valuable therapeutics. 
The oxytocin/vasopressin signalling system constitutes one of the most complex and 
important neuroendocrine systems in humans. There are four known receptor subtypes, the 
oxytocin receptor (OTR) and vasopressin receptor isoforms V1aR, V1bR and V2R7. These receptors 
belong to the largest subclass of the rhodopsin-β adrenergic receptor family (class A)8 and are 
activated by the two endogenous peptide ligands oxytocin and arginine-vasopressin. Despite the 
lack of a crystal structure, several strategies have attempted to identify and develop receptor 
probes to study the structure-activity relationships and molecular signalling properties of these 
GPCRs (summarized in Ref.9,10). Nonetheless, the structural homology of endogenous peptides 
and receptors is a major inconvenience and hampers the development of powerful molecular 
probes9. Although the oxytocin/vasopressin signalling system is linked to a diverse range of high-
profile disorders including preterm labour, cancer, pain, autism, anxiety, stress, depression, and 
cardiovascular diseases7,11,12, there is still a lack of selective receptor agonists and antagonists, 
which limits our ability to characterize the physiological and pathological function of each receptor 
subtype9,13. 
In humans and other mammalian species, oxytocin and vasopressin signalling displays an 
extensive repertoire of peripheral physiological functions, including uterine smooth muscle 
contraction during parturition, ejaculation, milk let-down, vasoconstriction and osmoregulation 
(summarized in Ref.14). Centrally, this neuropeptidergic system has been implicated in memory 
and learning, social cognition and aggressive behaviour15-18. Oxytocin (CYIQNCPLG-NH2) and 
arginine-vasopressin (CYFQNCPRG-NH2) are cyclic nonapeptides containing a disulfide bond 
between Cys-residues in positions 1 and 6, differing only in two positions in most mammals 
(residues 3 and 8)9. Oxytocin- and vasopressin-like peptides have been identified in all vertebrate 
animals, as well as in some invertebrate species19. These peptides are evolutionarily highly 
conserved and functionally related19,20. The arthropod orthologue of oxytocin and vasopressin, 
called inotocin (CLITNCPRG-NH2)21,22, also exhibits a high degree of structural conservation 
offering a unique opportunity to probe structure/function-relationships of the human oxytocin and 
vasopressin receptors to increase our molecular understanding of these GPCRs23. 
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In the present study, we isolated, cloned and characterized the inotocin receptor with its 
cognate ligand inotocin from the black garden ant (Lasius niger) and exploited its evolutionary 
relationship and structural similarity to the human vasopressin V1a and V1b receptors. Our approach 
aimed at demonstrating that exploring a highly conserved and widely distributed signalling system 
such as the oxytocin/vasopressin system is a good strategy for the discovery and development of 
much needed selective probes for the study of the four human receptor subtypes. To validate the 
pharmacological tools, we determined the molecular properties of the endogenous ant ligand-
receptor pair, in comparison to the previously identified inotocin receptor of the red flour beetle 
(Tribolium castaneum). Based on the molecular conservation of the insect and human signalling 
systems, we conducted in vitro pharmacological studies of the insect inotocin at the four human 
oxytocin/vasopressin receptors. Due to the observed binding and activation profile of the insect 
ligand, we probed the structure-activity relationship by replacing Arg8 of inotocin with its 
corresponding D-stereoisomer to investigate how this amino acid substitution influences ligand 
binding and selectivity. This approach successfully yielded a potent, selective and very stable 
antagonist of the human V1aR, which was validated in functionally-relevant ex vivo uterine 
contraction studies. These probes furthermore provided novel insights into the molecular binding 
features and evolution of the ligand-receptor pairs of the oxytocin/vasopressin signalling system.
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RESULTS 
Transcriptome analysis and discovery of the inotocin pre-prohormone and partial receptor 
sequences from L. niger. As previously published, insect neuropeptides have been discovered by 
genome-mining21, but it is challenging to derive full-length receptor sequences due to the size of 
the coding sequences and the presence of multiple introns. Therefore, we aimed to identify the 
inotocin precursor and its receptor in L. niger by transcriptome analysis. To reconstruct the 
transcriptome, we sequenced L. niger cDNA via paired end Illumina HiSeq 2000 Technology. The 
initially obtained 85,112,874 raw sequence read pairs were quality and length filtered and the 
remaining 90.1% high quality pairs were screened for rRNA reads, which lead to the removal of 
6.8% of the sequence read pairs. Hence, de-novo assembly for the reconstruction of the L. niger 
transcriptome was initiated with 71,435,903 of high quality mRNA read pairs. This resulted in 564.8 
megabases distributed over 380,930 contigs with a N50 of 3,308 base pairs (bp). These contigs 
represent different L. niger transcripts and isoforms. We identified 99.6% of a defined set of highly 
conserved genes. This near complete transcriptome was subject to a sequence similarity search 
using several insect inotocin precursor and receptor sequences as queries. It resulted in 125 hits 
for the receptor and two significant hits for the precursor namely the contigs comp45093_c0_seq1 
and comp45093_c0_seq2. These sequences represent the transcribed sequences of the inotocin 
precursor and receptor of L. niger. The top precursor hit exhibited a similar domain structure as 
compared to the human proteins (Fig. 1A). The second precursor hit was discarded as it was 
considered an artefact. The 125 receptor hits represent different isoforms and assembly artefacts 
of the most homologous receptors in the assembly. To verify that we have identified the inotocin 
receptor of L. niger, we reconstructed the phylogenetic relationship of the most relevant hits 
(multiple near identical contigs with different length per main hit). The resulting phylogenetic tree 
confirmed that we indeed detected the inotocin receptor of L. niger (Supplementary Fig. 1). The 
verified receptor and precursor sequences were used as templates for molecular cloning. 
 
Molecular cloning and characterization of the inotocin signalling system. The full length 
amplification product corresponding to the novel ant precursor was directly sequenced, and the full 
length amplification product corresponding to the novel ant receptor was cloned into a plasmid and 
its sequence confirmed by DNA sequencing. Multiple sequence alignments of precursor (Fig. 1B) 
and receptor (Supplementary Fig. 2) provided further evidence of the molecular similarity of insect 
and human oxytocin/vasopressin-like receptors. For functional characterization of the inotocin 
peptide-receptor system, the peptide inotocin was chemically synthesized and the cDNA encoding 
the L. niger inotocin receptor was cloned into a pEGFP plasmid for transient expression in 
mammalian cells. For pharmacological validation of the ant signalling system we determined 
affinity and potency of inotocin to its cognate receptor from L. niger and compared the data to the 
known ligand-receptor pair from T. castaneum. The affinity for the inotocin peptides was 
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determined via competitive radioligand binding experiments (Fig. 2A) on membrane preparations of 
mammalian cells transiently expressing these receptors. Inotocin displaced its tritiated analogue 
with a Ki of 6 and 10 nM at the ant and beetle receptors, respectively (Table 1). The functional Gq-
coupled receptor response was monitored by detection of the production and accumulation of 
inositol monophosphate (IP1), a downstream metabolite of D-myo-inositol 1,4,5-trisphosphate (IP3), 
following the activation of phospholipase C (Fig. 2B). The endogenous ligand inotocin is able to 
activate the ant receptor at low picomolar concentrations with an EC50 value of 22 pM, and the 
beetle receptor was activated with a potency of 350 pM (Table 2), in agreement with previous 
published data24. 
 
Pharmacological characterization of inotocin at the human oxytocin and vasopressin 
receptors. Based on the structural homology of the inotocin peptide, we pursued the 
pharmacological characterization of the endogenous inotocin on human OTR, V1aR, V1bR and V2R 
receptors. We determined the affinity of inotocin peptide to the human receptors (Fig. 2C and 
Table 1) and estimated the ability of this insect peptide to elicit a concentration-dependent 
functional response (Fig. 2D and Table 2). Inotocin exhibited nanomolar affinity to the human V1aR 
(Ki = 11 nM), V1bR (Ki = 12 nM) and OTR (Ki = 62 nM), but does not appear to displace [3H]-
vasopressin from the human V2R at concentrations <10 µM (Table 1). Interestingly, the insect 
ligand is a full agonist at the human V1bR (EC50 = 56 nM), but does not activate the V1aR or OTR at 
a detectable level (EC50 < 10 µM) (Table 2). Despite being unable to displace [3H]-vasopressin at 
the human V2R (Table 1), inotocin exhibited partial activation of this receptor with an EC50 > 1.5 
µM, possibly through direct allosteric agonism. 
 
Pharmacological characterization of the modified ligand [D-Arg8]-inotocin at the human 
oxytocin and vasopressin receptors. Previous studies indicated that the Arg in position 8 of 
vasopressin mediates ligand functionality and receptor selectivity in the human 
oxytocin/vasopressin family25-28. Additionally, the proline-arginine site is easily cleaved by enzymes 
such as trypsin29 and forms a well-known position to improve metabolic stability through 
introducing D-Arg instead of L-Arg30. Having in mind harnessing the insect system to guide 
development of novel and stable probes to study human GPCRs, we synthesised [D-Arg8]-inotocin 
and characterized it pharmacologically at the insect and human receptors (Tables 1 and 2). [D-
Arg8]-inotocin is a partial agonist (apparent maximum response Emax ~80%) at the inotocin 
receptors from L. niger and T. castaneum with a potency (EC50) of 1.2 and 12 nM, respectively, 
and an affinity (Ki) of 61 and 217 nM, respectively (Supplementary Fig. 3). Interestingly, the D-Arg8 
modification resulted in a selectivity profile switch at the human receptor subtypes; [D-Arg8]-
inotocin improved its binding affinity at human V1aR compared to inotocin (Ki = 1.3 nM; Table 2 and 
Supplementary Fig. 3), but did not exhibit any significant displacement at the human OT, V1b, V2 
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receptor isoforms (Ki > 4 µM) (Table 2 and Supplementary Fig. 3). [D-Arg8]-inotocin was not able 
to evoke a functional IP1 response at the human OT, V1a or V1b receptors (EC50 > 10 µM), yet 
retained a low potency response at human V2R (EC50 of 164 nM) possibly by direct allosteric 
agonism as observed with inotocin (Table 2 and Fig. S3). 
 
Competitive antagonism of [D-Arg8]-inotocin at the human V1aR. To investigate the inhibitory 
mechanism of [D-Arg8]-inotocin further, we quantified the concentration-dependent activation of 
the receptor by the endogenous ligand vasopressin in the absence and presence of a set of 
constant concentrations of [D-Arg8]-inotocin (30, 100, 300 and 1000 nM, respectively). Typical for 
a competitive antagonist, we observed a dextral displacement of the concentration-response 
curves of vasopressin, with no change in the Emax (Fig. 3B). To confirm a competitive antagonist 
action of [D-Arg8]-inotocin at the human V1aR, we performed Schild regression analysis. The 
regression of the concentration-ratio, which is a measure of the potency of a drug and the 
concentration of antagonist [D-Arg8]-inotocin was linear and had a slope of unity, indicating that 
the antagonism is indeed competitive. [D-Arg8]-inotocin is a competitive inhibitor of the human 
V1aR with approximately three orders of magnitude selectivity in affinity over the other 
oxytocin/vasopressin receptors. The pA2 value of this competitive antagonism has been calculated 
as 7.8 (Fig. 3B), corresponding to a functional affinity of approximately 16 nM. 
 
Identification of receptor residues responsible for the pharmacological profile of [D-Arg8]-
inotocin. Following the characterization of [D-Arg8]-inotocin as a subtype selective vasopressin 
V1a-receptor ligand, we wanted to rationalize this effect in terms of key ligand interactions in the 
context of the receptor binding site. Analysis of sequence differences between the human 
vasopressin and ant/beetle inotocin receptors should provide insights into the observed differences 
in functional and binding selectivity. To pinpoint the amino acid positions in the receptors that are 
accessible by ligands, i.e. residues in the upper part of the transmembrane (TM) helices and the 
extracellular loop (ECL) 2 facing the common GPCR binding cavity, we constructed homology 
models of the six receptors (human OTR, V1aR, V1bR and V2R; L. niger and T. castaneum inotocin 
receptors) using the crystal structures of the µ-opioid and orexin receptors31,32 as templates. Based 
on these models, 43 positions with side-chains facing the spacious inter-helical cavity were 
extracted from the global sequence alignment to construct a local structure-based binding site 
alignment (Fig. 4A and Supplementary Fig. 4). This approach offers a way to identify both 
conserved and different sequence positions, which are likely to influence peptide binding, 
selectivity and function. The sequence similarity of the binding site residues of the three human 
vasopressin receptors is within 74-88%, between the ant and beetle inotocin receptor 77%, and 
between the vasopressin V1a/V1b receptors and the two inotocin receptors 63%. In total, 21 (49%) 
positions of the binding cavity are conserved residues with similar properties in all receptors, e.g. 
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Glu1x35, Lys3x29, Glu/Asp45x49 (GPCRdb generic numbering33, which explains the binding of 
native inotocin to 5 out of 6 receptors (except human V2R, where allosteric agonism was 
observed). Furthermore, the binding site alignment shows 6 positions in the V1aR, i.e. Ala139(3x40), 
Ile192, Ser213(5x36), Met220(5x43), Ile330(7x34) and Ala334(7x38), which distinguish V1aR from V1bR and 
the inotocin receptors (Fig. 4A) and which could be responsible for the observed inactivity of native 
inotocin at V1aR while being a full agonist at V1bR (Table 2). Additionally, the 4th position in ECL2 
(Ile192 in V1aR) and position 7x38 contain an Arg and Met, respectively, in V1bR, V2R and OTR, 
while the corresponding residues in V1aR and the inotocin receptors have neutral and short side 
chains. This could be correlated to the lack of binding for [D-Arg8]-inotocin at the V1bR, V2R and 
OTR. 
 
Human serum stability of [D-Arg8]-inotocin. In addition to the valuable selectivity profile at the 
human oxytocin/vasopressin receptors, [D-Arg8]-inotocin was anticipated to be significantly more 
stable than its lead ligand inotocin as well as vasopressin due to dismantling the recognized trypsin 
Pro-Arg cleavage site by introducing the non-natural D-Arg residue29,34. The increased stability of 
[D-Arg8]-inotocin was confirmed in human serum by reversed-phase high performance liquid 
chromatography (RP-HPLC) in a 24 h time-course experiment (Supplementary Fig. 5). Native 
inotocin, vasopressin and melittin were used as controls. Whilst vasopressin (t½ = 1.0 h), inotocin 
(t½ = 2.8 h) and melittin (t½ = 0.7 h) were fully degraded within 24 h, >70% of [D-Arg8]-inotocin was 
still present after 24 h.  
 
Concentration-dependent inhibition of human myometrial contractions by [D-Arg8]-
inotocin. To assess the functional relevance of this novel human V1aR antagonist we tested [D-
Arg8]-inotocin in a well-recognised ex vivo human uterine contraction study14,35. After obtaining 
stable contractions of prepared tissue, human myometrium was stimulated with vasopressin (0.5 
nM). The effects of [D-Arg8]-inotocin at these contractions were then investigated and compared to 
the small molecule V1aR antagonist SR49059 (relcovaptan)10. Both ligands caused a 
concentration-dependent decrease in vasopressin-augmented myometrial contraction amplitude 
and area-under-the-curve (Fig. 5A,B). For [D-Arg8]-inotocin, this became significant at 10 nM for 
amplitude (P<0.01) (Supplementary Fig. 6A) and 100 nM for area-under-the-curve (P<0.05) (Fig. 
5D; Supplementary Fig. 6B). For SR49059, at 30 nM we observed a significant reduction in uterine 
contraction for both amplitude of contraction and area-under-the-curve (P<0.05 and P<0.001, 
respectively) (Supplementary Fig. 6C,D). Some contraction recovery was noted for both ligands 
upon washout (Fig. 5A,B). The effect of 100 nM [D-Arg8]-inotocin and SR49059 on amplitude of 
contraction and area-under-the-curve compared to the vasopressin (time-equivalent) and control 
activity are shown (Fig. 5C,D). Effects of [D-Arg8]-inotocin and SR49059 at other concentration (1, 
3, 10 and 30 nM) are presented in Supplementary Fig. 6. [D-Arg8]-inotocin significantly reduced 
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contraction amplitude by 22.9% (Fig. 5C) and showed a clear reduction of area-under-the-curve by 
36.6% (Fig. 5D). SR49059 (100 nM) significantly reduced contraction amplitude and area-under-
the-curve by 54.8% (Fig. 5C) and 72.1%, respectively (Fig. 5D). Contractions under vasopressin 
alone however persisted without significant loss of amplitude or area-under-the-curve for the 
duration of the experimental protocol (Fig. 5C-F). [D-Arg8]-inotocin did not have any effect on 
myometrial contractions that were augmented with oxytocin (0.5 nM) (Fig. 5G).  
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DISCUSSION 
The oxytocin/vasopressin GPCR family of receptors and neuropeptide ligands are part of a 600-
million-year-old signalling system regulating many fundamental functions36. Advances in 
sequencing, molecular cloning and the expression of receptors in several heterologous systems 
have contributed to a renewed interest in structural and functional studies of members of this 
receptor family. The physiological complexity and therapeutic relevance of the oxytocin and 
vasopressin receptors render this receptor family as one of the most studied GPCRs. Therefore, 
oxytocin/vasopressin receptors represent interesting experimental models to study GPCR function 
and ligand development9. Linking the highly homologous receptor subtypes to their specific 
physiological and pathological functions has been a challenging and tedious process, particularly 
due to the lack of a complete set of receptor subtype-selective ligands9. To address this issue, we 
have recently proposed a strategy that focusses on the discovery and characterization of 
oxytocin/vasopressin-like ligands from nature and that takes advantage of the ancient character, 
high homology, conservation and distribution of the oxytocin/vasopressin signalling system 
throughout the animal kingdom, including humans9. Adopting this strategy has led to the discovery 
and characterization of an ant inotocin ligand pair in this work, which also formed an ideal template 
for the development of the novel, selective and stable human vasopressin V1a receptor antagonist 
[D-Arg8]-inotocin. [D-Arg8]-inotocin is not only an excellent new research tool as will be discussed 
in the following paragraphs, but also may serve as a promising new starting point for future drug 
design and development efforts targeting V1aR-related disorders. 
Previous mutagenesis studies on the V1aR in combination with vasopressin and its 
analogues have shown that residue 8 of vasopressin contributes to high affinity peptide binding in 
the V1aR25,37. In the present study, we utilized pharmacological measurements of ant vasopressin-
orthologue inotocin, its [D-Arg8]-inotocin analogue, and endogenous human vasopressin in 
heterologous systems expressing the human OTR, V1aR, V1bR and V2R, as well as two 
evolutionary-related inotocin GPCRs from ants and beetles. In a comparative approach, cell-based 
in vitro data were applied to receptor homology models to explain the observed pharmacological 
effects. 
The engineered peptide ligand [D-Arg8]-inotocin is a potent, stable and competitive V1aR-
antagonist with a 3,000-fold binding selectivity for the human V1aR over the other three subtypes, 
OTR, V1bR and V2R. We note that the observed partial activation of the human V2R by inotocin and 
[D-Arg8]-inotocin is likely due to direct allosteric agonism, which has been described for other 
GPCRs previously38-41. The insect-derived peptide probe [D-Arg8]-inotocin significantly reduced the 
contraction amplitude and area-under-the-curve in vasopressin-augmented tissue, albeit there 
were no detectable effects on myometrial contractions that were augmented with oxytocin. This 
effect is in line with the reduction in amplitude of contraction and area-under-the-curve with the 
commercially available small molecule V1aR antagonist SR49059 (relcovaptan)10, although [D-
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Arg8]-inotocin is less potent. From a therapeutic viewpoint, the inhibition of human V1aR and the 
partial activation of V2R receptor isoforms by [D-Arg8]-inotocin, although to date there is no 
compelling evidence for the expression of V2R receptor subtypes in human uterine tissue, could 
have synergistic effects leading to the reduction in contractility and supporting tocolysis42,43. 
To provide a molecular explanation for the interesting pharmacological profile of [D-Arg8]-
inotocin, we built homology models for the human OT, V1a, V1b and V2 receptors as well as the two 
evolutionary-related insect receptors from ants and beetles to identify the binding site residue 
positions. To deduce structural requirements for the binding of the two nonapeptides inotocin and 
[D-Arg8]-inotocin, we reasonably assumed – supported by radioligand displacement data – that the 
conserved part of the peptide would engage and occupy the same space of the orthosteric 
receptor binding pocket of the receptors allowing us to obtain novel insights of the molecular role of 
the L- to D-Arg substitution. Our data clearly indicates that the stereochemistry of Arg8 is essential 
for binding to the proposed binding pocket of human OTR, V1aR and V1bR, while [D-Arg8]-inotocin 
only binds to the human V1aR and the two inotocin receptors without detectable affinity to the 
human V1bR, V2R and OTR. Interpretation of the observed pharmacological effects leads to the two 
hypotheses that either (i) the Arg8/D-Arg8 side chain interacts with different residues, with the 
putative interaction partner of Arg8 being conserved in all subtypes, while that of D-Arg8 only being 
present in the inotocin receptors and V1aR, or that (ii) the Arg8/D-Arg8 side chain interacts with the 
same position and that a nearby residue(s) hinders the interaction of the D-Arg8 side chain to the 
position of importance in three of the human GPCRs. Importantly, the observed effects of the Arg8 
stereochemistry in inotocin/[D-Arg8]-inotocin does not apply to vasopressin/[D-Arg8]-vasopressin, 
as the first pair shows similar binding affinities in the V1aR (11 and 1.3 nM, Table 1), while previous 
studies have shown ~200-fold difference in affinity of the latter peptide pair (4.2 and 781 nM)32,43. 
While this does not exclude similar binding modes for inotocin and vasopressin, it clearly shows 
different binding modes for [D-Arg8]-inotocin and [D-Arg8]-vasopressin and different spatial 
locations of Arg8 in the binding site. Furthermore, neither vasopressin (Table 2), nor the non-
selective vasopressin V2R agonist, desmopressin (1-desamino-8-D-arginine-vasopressin; dDAVP), 
activates inotocin receptors (Supplementary Fig. 7). 
The binding site alignment does not pinpoint to a unique position with an acidic or hydrogen 
bond-accepting residue in the binding site of [D-Arg8]-inotocin binding receptors, thereby 
weakening hypothesis (i) of different interaction partners for the guanidine moiety of Arg8/D-Arg8. 
Instead, the alignment revealed two positions, 7x38 and the 4th residue in ECL2 (Ile192 in V1aR), 
which distinguish the [D-Arg8]-inotocin binding receptors from the non-binding ones. Importantly, 
these two positions are in proximity of the negatively charged Glu1x35 and Asp/Glu45x49, 
respectively, which are conserved within the vasopressin and inotocin receptors, and potential 
interaction partners to the side-chain of Arg8/D-Arg8. Residue Glu1x35 is located in the second 
helical turn and Asp/Glu45x49 in ECL2 next to Cys45x50 forming a disulphide bridge to TM3 and 
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hence both positions are conserved in structure as well as in sequence. Of note, position 45x49 
and 45x50 in ECL2 have been considered to be essential for high-affinity agonist binding and 
receptor activation and to be highly conserved throughout the neurohypophyseal hormone receptor 
subfamily of GPCRs44. 
Compared to V1bR, V2R and OTR, where position 7x38 is a methionine, the short side chain 
residues Ala, Ser and Thr occupy this position in V1aR and the two inotocin receptors, respectively. 
The steric hindrance of the longer methionine side chain in combination with the stereochemistry of 
Arg8/D-Arg8 offers a potential explanation for the lack of [D-Arg8]-inotocin binding to V1bR, V2R 
and OTR, if Glu1x35 is a key interaction partner (Fig. 4B). Arg8 and D-Arg8 could approach the 
putative salt bridge partner from slightly different directions and, while the short side chains allow 
unhindered access of both, Met7x38 in V1bR, V2R and OTR may sterically interfere with D-Arg8 
only. Additionally, the structural neighbour, Lys2x65 in V2R (Asp in the other receptors), provides a 
structural explanation for the marked reduction in affinity of inotocin in V2R compared to the other 
receptors (Table 1) likely due to a charge repulsion – an explanation that could also apply if the 
positively charged peptide C-terminus was the interaction partner of Glu1x35. Ile192 in V1aR is a 
structural neighbour to Asp/Glu45x49 on the adjacent β-strand and along with Gln and Thr at the 
two inotocin receptors, is a non-positively charged residue. In comparison, this same position holds 
an arginine in V1bR, V2R and OTR. Arginine in this position is likely to form a salt bridge to 
Asp45x49 in V1bR, V2R and OTR, blocking part of the interaction area of the aspartate (Fig. 4C). If 
the stereochemistry of Arg8/D-Arg8 results in a different location of the guanidine moiety relative to 
the Asp45x49, it is likely that the presence of an arginine in this position may prevent only [D-
Arg8]-inotocin from forming a salt bridge, thus abolishing or severely impeding binding of this 
peptide in V1bR, V2R and OTR. This hypothesis also puts the Arg8 guanidine of inotocin in the 
vicinity of the structurally neighboring Tyr115(23x50) in V1aR (Fig. 4C), which together with position 
45x49 has also been hypothesized to interact with the Arg8 side chain of vasopressin37,44. Since 
both DAVP and dDAVP bind potently to V2R37, but [D-Arg8]-inotocin does not bind (Table 1), the 
observed affinity differences in V1aR, indicates overlapping binding modes of inotocin and 
vasopressin, but not of [D-Arg8]-inotocin and [D-Arg8]-vasopressin. 
At a more general level, the function of a peptide on a receptor is not as logically reflected 
in the ligand-receptor interactions as the binding affinity, whereas our structural sequence 
alignment of the receptor binding site may indicate which residues are responsible for the 
pharmacological differences observed from the experimental data. It is tempting to ascribe this 
observation to the unique glutamate in position 45x49 of the L. niger inotocin receptor, which may 
in general favour activation relative to the aspartate of the other receptors and, additionally, 
activation by the guanidine of inotocin relative to that of [D-Arg8]-inotocin. Moreover, this would 
further support position 45x49 as the crucial interaction partner of the Arg8/D-Arg8 side chain and 
not the alternative Glu1x35, which is conserved in all six receptors.  
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Another and more clear-cut pharmacological observation is that, in contrast to the agonistic 
effects of inotocin and [D-Arg8]-inotocin on the inotocin receptors (plus inotocin on V1bR), both 
peptides exert antagonist effects on V1aR. The search for sequence differences, which may offer 
an explanation for this observation, results in only two positions, 3x40 and 7x34, that clearly 
distinguish V1aR from V1bR and the two inotocin receptors. This lack of activation is clearly ligand 
dependent, as the related neuropeptide, vasopressin, potently activates V1aR indicating that the 
responsible amino acids are one or more of Tyr2, Phe3 and Gln4 in vasopressin, which differ from 
the corresponding positions in inotocin, Leu2, Ile3 and Thr4. Assuming that vasopressin, relative to 
inotocin, forms some additional contacts to V1aR that are responsible for activation, neither 
Ala139(3x40) nor Ile330(7x34) provides an explanation for this fact. However, position 3x40 in the 
narrow bottom part of the binding site has together with 5x50 and 6x44 been shown by the 
research team of Kobilka45 to form a ‘conserved core triad’ in other class A receptors. These three 
positions are dominantly Ile/Leu/Val, Pro and Phe/Tyr, respectively, and rearrange their 
hydrophobic packing during movement of TM6 and receptor activation. Additionally, the 
combination of NMR and mutagenesis experiments showed that increasing the van der Waals 
contact area by Val-to-Ile exchange in position 3x40 of a thermostabilised β1 adrenoceptor shifts 
the receptor towards an active state46. Considering a similar activation switch in the receptors 
studied here, we performed in silico exchange of positions 3x40 and 6x44 in the crystal structure of 
the active state µ-opioid receptor 45 with those of V1bR (Fig. 6A). In our V1bR homology model of the 
inactive state, Tyr290(6x44) and Thr122(3x40) forms an inter-helical hydrogen bond (Fig. 6B). 
However, the movement of TM6 in the active state allows Tyr290(6x44) to form a hydrogen bond to 
the backbone carbonyl of the residue in position 5x461. This position is a so-called helical ‘bulge’ 
residue, i.e. an additional 5th residue in a helical turn 33 and, together with the conserved Pro5x50, 
this changes the normal helical hydrogen bonding pattern making the backbone carbonyl 
accessible to Tyr290(6x44) (Fig. 6A). Assuming a conformational change analogous to those 
observed in the crystal structures45 the conformation of Tyr290(6x44) is likely further stabilized by an 
additional hydrogen bond to Thr122(3x40). Among the receptors studied here, only V1aR lacks the 
hydrogen bonding residue in position 3x40 that potentially stabilizes an active receptor state (Fig. 
6C). Thus, our data indicates that the lack of this hydrogen bond due to Ala139(3x40) in V1aR results 
in an increased energy barrier of activation, which can explain the different pharmacological 
actions of inotocin and [D-Arg8]-inotocin on V1aR vs. V1bR and the two inotocin receptors. 
Interestingly, the mouse V1aR does contain a serine in position 3x40, which may explain observed 
pharmacological differences relative to the human receptor47. Additionally, mammalian oxytocin 
receptors have a phenylalanine in position 6x44 (Fig. 6), which also prevents formation of the 
hydrogen bonding network: this also agrees with the observed lack of activation of the human OTR 
by inotocin, despite the peptide binding. This further implies that vasopressin may have evolved to 
compensate for the increased activation energy barrier, particularly through residues Tyr2, Phe3 
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and Gln4 of the peptide mediating key contacts. This may be a fine example of co-evolution of 
peptide and receptor, i.e. arginine-vasopressin and the human V1aR.  
More than 60 years have passed since the discovery, synthesis and characterization of 
oxytocin and vasopressin, yet there still remains a shortage of agonists and antagonists with good 
selectivity for the four known receptor subtypes48. The development of antagonists for vasopressin 
receptors is challenging due to the large degree of structural homology within the four receptor 
subtypes and their inter-species differences. Currently, there are no ligands in clinical use with 
selective antagonist activity for the V1aR over the V1bR and V2R. For this reason, novel strategies 
for ligand discovery and design represent a powerful option and a promising opportunity to outpace 
and effectively tackle this problem. Vasopressin antagonists are valuable pharmacological tools for 
investigating the pharmacological functions of the nonapeptide vasopressin. Previous studies have 
demonstrated that the carboxy-terminal position in vasopressin is a critical structural requirement 
for receptor activation but not binding49. To guide the rational design of novel peptide antagonists 
based on the moiety of the native ligand, it is necessary to identify conserved and non-conserved 
functional receptor domains involved in receptor binding and activation, such as residue positions 
192 in V1aR, 3x40, 45x49, 6x44 and 7x38 that were described and analyzed in this study. 
 
CONCLUSION 
Oxytocin/vasopressin receptors are promising targets for important diseases, including 
cardiovascular and neurological disorders. Despite extensive efforts there is demand for 
oxytocin/vasopressin ligands as therapeutics or modulators to probe the biological function of 
individual receptor subtypes. In a novel strategy that is broadly applicable to the development of 
selective ligands for the oxytocin/vasopressin family, we explored the evolutionary conservation of 
this signalling system to discover and subsequently engineer a competitive, subtype-selective and 
stable human V1aR-antagonist. We gained deeper insights into ligand-receptor pharmacology 
through integrated and iterative structure modelling and pharmacological evaluation. In fact, 
understanding the molecular mechanisms responsible for agonist and antagonist binding is critical 
and the information derived from our study may be useful for the rational design of potential 
therapeutic agents targeting oxytocin/vasopressin receptors. Furthermore, we have demonstrated 
the utility of the engineered inotocin ligand in a translational ex vivo human myometrial contractility 
study. Therefore, we consider that [D-Arg8]-inotocin has great potential to advance our 
understanding of V1a-receptor physiology and its associated role in disease. Overall, this study 
establishes proof-of-concept for exploiting insect-derived neuropeptide probes for human ligand 
development, which may be applied to other GPCRs.   
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METHODS 
Transcriptome analysis. For the transcriptome analysis, 96 Lasius niger workers were used from 
laboratory colonies established at the IST Austria, and reared under a 14 h day (27°C) – 10 h night 
(21°C) cycle. Total RNA was extracted from 48 pools of two workers each, using the Maxwell® 16 
Research instrument and the Maxwell® 16 LEV simplyRNA Tissue Kit (Promega, Mannheim, 
Germany). After extraction, all 48 samples were pooled resulting in a single sample with an overall 
amount of 24 µg total RNA based on NanoDrop measurements (A.V. Grasse, unpubl.). The RNA 
was sent to Eurofins MWG GmbH (Ebersberg, Germany) for quality control, preparation of a 2x 
normalized, random-primed cDNA library and subsequent sequencing on the Illumina HiSeq 2000 
platform, applying the 2x 100 bp paired-end read module. The raw sequence reads were checked 
with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, version 0.11.2), filtered 
and trimmed with PRINSEQ lite50 (version 0.20.4) with the following parameters: min_len 40, 
min_qual_mean 28, trim_tail_left 8, trim_tail_right 8, and trim_ns_right 1. To remove all rRNA, 
SortMeRNA51 (version 1.8) with the default eight databases and default parameters was applied. 
For de-novo transcriptome assembly of the high quality mRNA read pairs, Trinity52 (r2013-02-25) 
was used. The resulting contigs were tested for completeness via CEGMA53 (version 2.5). To 
identify contigs representing the precursor and receptors, a BLAST54 search via TBLASTN, in 
BLAST+ (version 2.2.29) against the assembly as database was carried out. Default parameters 
with an e-value cut-off of 1e-4 were used. As query the amino acid sequences of the following 
inotocin precursors and receptors were used: Harpegnathos saltator (GenBank accession 
DAA35079.1, XM_011149198.1, XM_011153432.1), Atta cephalotes (DAA35080, 
XP_012061245.1), Camponothus floridanus21, Acromyrmex echinatior (XM_011067026.1, 
EGI60623.1), Solenopsis invicta (XM_011161311) and Pogonomyrmex barbatus (XM_011641193, 
XM_011641194.1, XM_011641195.1). The multiple alignments of the blast-hits with the query 
sequences were calculated with Clustalw55 and MAFFT56. For the phylogenetic reconstruction of 
described receptors versus the best blast hits, we aligned 30 well described receptors with the top 
blast hits based on e-value, with Clustalw. The phylogenetic tree was then calculated via maximum 
likelihood phylogenetic reconstruction with RAxML (version 8.2.4)57, with the 
PROTGAMMABLOSUM62 model and 100 bootstrap replicates. For re-rooting and visualization of 
the phylogenetic tree we used Dendroscope58. 
 
cDNA cloning of the inotocin precursor. The full length precursor was obtained via Rapid 
Amplification of 3’ cDNA Ends (3’ RACE) technology. RNA of whole workers from laboratory 
colonies was extracted using Quick-RNATM MiniPrep kit (Zymo Research, Irvine, USA) and reverse 
transcription was done using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Carlsbad, USA) and polyT primer 5’-GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT-3’. 
First PCR was performed using Phusion Hot Start II polymerase (Thermofisher Scientific, 
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Waltham, USA) and primers polyT-end CTACTACTACTAGGCCACGCGTCGACTAGTAC and FW 
ATGCTAAAGAAGCTTGTCATTTTTGCGAG. Nested PCR was carried out using the first PCR 
product as template with a FW-nested primer 5’-AATTTTCCTGAGTTACGCTTGTTTGATTAC-3’ 
and the polyT-end primer. PCR fragments (~500 bp) were extracted, purified using GeneJET Gel 
Extraction kit (Thermofisher Scientific, Waltham, USA) and sequenced at LGC Genomics (Berlin, 
Germany) using the FW-nested primer. After determining the unknown 3’ sequence, one more 
PCR was performed using FW and Seq-Rev AAGTTGAAACATCAAAGTAATAAGCAAAAACTATG 
primers and cDNA as template. The obtained PCR fragment (full length inotocin precursor) was 
directly sequenced using the Seq-Rev primer to obtain the full length reading frame of the 
precursor sequence.  
 
cDNA cloning of inotocin receptor. The cDNA of the ant inotocin receptor was obtained by 
reverse transcription using the OneStep RT-PCR kit (Qiagen, Venlo, The Netherlands) and RNA 
isolated from L. niger as a template; the following primers were used: 5’-
ATGTCGTATGACTCGAATACGTC-3’ (sense) and 5’-TCAGCCGAATATCTTTGAACTCG-3’ 
(antisense). Blunt end ligation of the PCR product with pJET1.2 vector was carried out at 4°C 
(Clone Jet PCR cloning kit, Thermo Scientific Waltham, USA). Successful cloning was determined 
by digest using restriction endonuclease BglII (Thermo Scientific, Waltham, USA) and DNA 
sequencing of the plasmid containing the amplification product corresponding to the full length 
receptor (Microsynth AG, Balgach, Switzerland). For cellular expression, the receptor cDNA was 
cloned into the pEGFP-N1 vector at the restriction sites EcoRI and KpnI using the primers 5’-
ATTCGAGAATTCATGTCGTATGACTCGAATACG-3’ (sense) and 5’-
ACGCACGGTACCGTGCCGAATATCTTTGAACTCGCAAGTCGTGAAATTCTAG-3’ (antisense). 
This resulted in a plasmid encoding the L. niger inotocin receptor together with a C-terminal GFP 
fusion protein. The cDNA pXN-INTR from T. castaneum was kindly provided by Yoonseong Park 
(Department of Entomology, Kansas State University59,60). Similarly, the beetle inotocin receptor 
was cloned into pEGFPN1 for cellular expression utilizing the KpnI and AgeI restriction sites and 
the primers 5’-ATTGGAGGTACCATGGACATCTCTGAGAACTCTACG-3’ (sense) and 5’- 
ATCGTCACGACGACCACCCCACCGGTCGCCACCATGGTG-3’ (antisense). Human receptor 
constructs encoding for the OTR, V1aR, V1bR and V2R were prepared and used as reported 
previously35. 
 
Database deposition. Nucleotide sequences corresponding to the coding sequences of the L. 
niger inotocin prepro-hormone and receptor were deposited in GenBank under the accession 
numbers KX266837 and KX266836, respectively. The raw sequence read files were deposited 
under the bioproject PRJNA352917; the sequence reads can be found in the short read archive: 
accessions SRR5007208 and SRR5007267. 
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Peptide synthesis. Peptides were assembled manually via Boc-SPPS using the HBTU-mediated 
in situ neutralization protocol61,62. After HF cleavage63, the crude peptides were purified by 
preparative RP-HPLC (Vydac C18 column, 300 Å, 10 µm, 250 x 21.2 mm) using a linear gradient of 
0-50% B (solvent A, H2O/0.05% TFA; solvent B, 90% CH3CN/10% H2O/0.043% TFA) in 50 min at 
8 mL min-1 while monitoring UV absorbance at 226 nm. Air oxidation was carried out in 0.1 M 
NH4HCO3 buffer at 25ºC and a peptide concentration of 100 µM. Oxidation, deprotection and 
degree of purification were monitored by mass spectrometry (MS) on a LCT-TOF mass 
spectrometer equipped with an electro-spray ionization source (ESI), by analytical RP-HPLC using 
a Vydac (Grace, Epping Vic, Australia) C18 column (300 Å, 5 µm, 250 x 4.6 mm) at 214 nm and by 
ESI-LC-MS on a Phenomenex (Torrence, USA) Jupiter LC-MS C18 column (90 Å, 5 µm, 250 x 2 
mm) on a SCIEX QSTAR Pulsar QqTOF mass spectrometer (Applied Biosystems, Carlsbad, USA) 
equipped with an atmospheric pressure ionization source, running a linear gradient 0-50% B over 
50 min with a flow rate of 1 mL min-1 for RP-HPLC and 200 µL min-1 for LC-MS. The synthesized 
peptides were of >95% purity determined by analytical RP-HPLC monitored at 214 nm. 
 
[3H]-inotocin synthesis. Fmoc-L-[4,5-3H]-leucine obtained by catalytic tritiation of Fmoc-4,5-
dehydro-L-leucine (S.A. = 112.6 Ci mmol-1) was added to the protected precursor peptide 
(CLITNCPRG-NH2) on PAL resin (Bachem, Bubendorf, Switzerland) using a standardised Fmoc 
protocol64. After the addition of a terminal cysteine residue the peptide was cleaved from the resin, 
deprotected and the disulfide bond was formed by bubbling air through the 0.1 M buffer solution 
(AcONH4, pH = 8.4) of the peptide. After radio-HPLC purification the [3H]-inotocin (C[4,5-
3H]LITNCPGR-NH2, radiochemical purity > 99.9%; specific activity = 55.7 Ci mmol-1) was prepared 
in a solution of H2O:EtOH 4:1 (v/v) at 1 mCi mL-1.  
 
Cell culture and transient receptor expression. Chinese Hamster Ovary cells (CHO) were 
cultured in HAM’s F12 supplemented with 10% fetal bovine serum (FBS), 1% PenStrep (all from 
Sigma-Aldrich, Munich, Germany) and grown in a humidified atmosphere of 37°C, 5% CO2 and 
passaged on average twice per week. CHO cells were used for expression of inotocin receptor (L. 
niger, T. castaneum). Cell transfections were carried out with 10 μg of plasmid using Lipofectamine 
LTX (Life Technologies, Invitrogen, Carlsbad, USA) for invertebrate receptors. For the expression 
of human OTR, V1aR, V1bR and V2R, HEK293 cells were transfected using jetPRIME (Polyplus 
Transfections, Illkirch-Graffenstaden, France)35. Cells were maintained in DMEM (GE Healthcare 
Hy Clone™, Logan, USA) supplemented with 10% FBS and 1% PenStrep. Fluorescence and 
receptor expression was confirmed via epifluorescence microscopy 24 h post-transfection. 
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Radioligand binding assays. Binding experiments were performed on transient receptor 
expressing membrane preparations (10-50 μg per assay), which were incubated with radioligand 
and peptide in 100 μL buffer containing 9 mM MgCl2, 25 mM Hepes, 0.15 mM bacitracin, 0.0015% 
(w/v) apoprotinin and 0.1% (w/v) bovine serum albumin. [Tyrosyl-2,6-3H]oxytocin, 47.4 Ci mmol-1 
and [[phenylalanyl-3,4,5-3H]-phenylalanyl-(N)-8-arginine]vasopressin, 61.2 Ci mmol-1 were from 
PerkinElmer Life Sciences, Warwick, USA; synthesis of [3H]-inotocin was described above. 
Displacement of radioactive ligand was assayed in the presence of logarithmically-spaced 
concentrations of competing ligand or control oxytocin/vasopressin peptides. After 2 h at 20°C, the 
reaction was terminated by rapid filtration over glass fibre filters (102 x 258 mm) (Filtermat A 
Wallac) previously soaked for 5 min in polyethylenimine 0.3% (v/v) in TRIS buffer (25 mM), to 
minimize unspecific binding. Unbound ligands were washed off (Skatron Cell Harvester). 
Displacement of radioactive ligand was assayed in the presence of saturating concentrations (10 
µM) of oxytocin, vasopressin or inotocin, respectively, to determine non-specific binding. For the 
displacement at the human OTR, V1aR, V1bR and V2R the normalization to 100% refers on average 
to 0.49, 1.4, 0.36, 1.1 pmoles of ligand bound per milligram of membrane for human OTR, V1aR, 
V1bR and V2R, respectively. Bindings of [3H]-AVP and [3H]-OT were performed with a radioligand 
concentration dependent on the Kd of each receptor subtype (1.5, 0.6, 0.1 and 1.2 nM for OTR, 
V1aR, V1bR and V2R). Membranes (30-50 μg) expressing human OTR, V1aR, V1bR and V2R, were 
assayed for displacement with an excess of inotocin or [D-Arg8]-inotocin, and vasopressin or 
oxytocin (10-11 to 10-5 M) as positive control for each receptor (n ≥ 3, except where otherwise 
stated). For the displacement at the insect receptors the normalization to 100% refers on average 
to 0.65 and 0.69 pmoles of ligand bound per milligram of membrane for inotocin receptor from L. 
niger and T. castaneum, respectively. Bindings of [3H]-inotocin to membranes (10 μg) expressing 
INTR from L. niger, or [3H]-inotocin to membranes (10 μg) expressing INTR from T. castaneum, 
respectively, were assayed for displacement with an excess of inotocin (10-11 to 10-5 M) (n ≥ 3, 
except where otherwise stated). Kd values of inotocin receptors were determined from saturation 
binding experiments to be 0.9 nM (L. niger) and 2.7 nM (T. castaneum). Specific binding was 
calculated by subtracting the non-specific binding from the total binding. IC50 values were obtained 
by fitting the data to a three-parameter logistic Hill equation. Inhibition constants (Ki) were 
calculated from IC50 using the a method by Cheng and Prusoff65. 
 
Functional receptor activation assays. Activation of Gq-signalling via the human V1aR, V1bR and 
OTR, as well as the insect INTR was measured by inositol-1-phosphate (IP1) quantification using 
an IP1 Tb kit (Cisbio, Codolet, France). Transfected cells were seeded in 96 well-plates, with a cell 
density of 104 cells per well. Cell culture media was removed from the wells after 6 h and 70 μL of 
peptide of interest at the desired concentrations prepared in IP1 1X Stimulation Buffer was added. 
Samples were measured in technical triplicates. After 1 h incubation at 37°C, 15 μL of IP1-d2 was 
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added, following the same volume of Ab-cryptate. After 1 h of incubation, activation was GPCR 
quantified via fluorescence measurement (SynergieH4, Biotek Instruments, Winooski, USA) using 
the ratio 665/620 nm. Activation of Gs-signalling via the human V2R was measured using a 
luciferase reporter assay. HEK293 transiently expressing V2R were co-transfected with the 
pGL4.29 [luc2P/CRE/Hygro] (Promega, Mannheim, Germany) plasmid. After ligand stimulation, 6 h 
incubation at 37°C, medium was removed and cells were kept at -80°C for at least 12 h before 
lysis. The measured luciferase counts (SynergieH4) were corrected using the fluorescent intensity 
per well and normalized to the maximum activation of oxytocin/vasopressin peptides. For cell-
based functional assays (luciferase and IP1), subtraction of the negative control (stimulation buffer) 
was applied to all data set. The normalization was performed to the highest value of the positive 
control from at least 4 independent experiments. Data were fitted using GraphPad Prism5 with an 
equation for non-linear regression (sigmoidal, slope fit of 1). Values are reported as mean ± SEM. 
For Schild regression analysis, the concentration-ratio (r) has been obtained division of the 
increased EC50 (right-shift; due to the functional antagonism) in the presence of [D-Arg8]-inotocin 
by the EC50 without the peptide. The logarithm of the concentration-ratio has been plotted vs. the 
logarithm of the concentration of [D-Arg8]-inotocin to obtain the pA2 value, which is defined as the 
negative logarithm of the molar concentration of the antagonist producing a concentration-ratio of 
2. 
 
GPCR homology modelling and in silico analysis. Template selection for the homology 
modelling was performed in GPCRdb66 using the human V1aR sequence as the query and 
selecting the µ-opioid31 and orexin32 crystal structures downloaded from the Protein Data Bank 
(rcsb.org/pdb)67 as templates. Sequences of the four human receptors and the beetle receptor 
were downloaded from the UniProt Knowledgebase uniprot.org68 (V1aR: P37288, V1bR: P47901, 
V2R: P30518 and OTR: P30559; T. castaneum D6WPA3), and the ant inotocin receptors was 
obtained by transcriptome mining and confirmed by PCR and sequencing. Multiple sequence 
alignment between V1aR, V1bR, V2R, OTR and the two invertebrate templates was created by 
manually adjusting the structure based sequence alignment from GPCRdb and adding the two 
inotocin receptors using ClustalX55. Homology models were constructed in MODELLER69, version 
9.15; since they are only used for comparing structural positions, the optimization was disabled by 
using the "very_fast" keyword. The residues of the inter-helical binding site was defined in PyMOL 
(The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.) by the residues 
comprising the van der Waal surface within the helical bundle and the surface of the ECL2 nearest 
to the cavity, thus extracted from the overall sequence alignment. The inotocin and [D-Arg8]-
inotocin fragments used to illustrate the selectivity hypotheses were built and manually inserted 
into the binding site in Maestro (Maestro, version 10.3, Schrödinger, LLC, New York, NY, 2015). In 
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silico amino acid exchange was performed using the mutagenesis wizard in PyMOL on the µ-
opioid active state crystal structure45 downloaded from the PDB.  
 
Serum stability assays. Serum stability was tested as described previously70. Briefly, serum was 
obtained prepared from human blood (self-donor), allowed to coagulate for 2 h at 23°C and 
centrifuged at 12,000 x g for 10 min. Peptides (100 μM) were incubated in serum for 2, 4, 6, 8, 10 
and 24 h at 37°C. To evaluate peptide stability, aliquots (25 μM) were analysed via RP-HPLC 
(UltiMate 3000, Thermo Scientific Dionex, Vienna, Austria) on a C18 column (Phenomenex Kinetex, 
Aschaffenburg, Germany) with a 3% gradient using 0.1% (v/v) TFA and 90/10/0.1% (v/v/v) 
acetonitrile/H2O/TFA as eluents. Half-life (t1/2) of peptides was calculated using non-linear 
regression analysis using Graph Pad Prism.  
 
Human myometrial contractility assays. Biopsies of human myometrium were obtained during 
pre-labour elective Caesarean Section (CS) delivery at term gestation (38-41 weeks) at Liverpool 
Women’s Hospital NHS Foundation Trust, Liverpool UK. At surgery, a biopsy measuring approx. 1 
cm3 was cut from the upper lip of the lower uterine incision site and placed into Hanks Balanced 
Salt solution at 4°C.  All women provided written informed consent and ethical approval was 
sought and granted by the Local Research Ethics Committee (REC Ref: 10/H1002/49) and by the 
Research and Development Director of Liverpool Women’s NHS Foundation Trust, Liverpool, UK. 
Multiple strips were dissected and measured as previously described35,71. Data were analysed 
using OriginPro9.0 Software (OriginLab, Northampton, USA). Contractile activity was measured by 
calculation of the integral area-under-the-tension-curve (AUC, arbitrary units) and mean maximum 
amplitude of contraction (expressed in mN). Contractile activity in the final 25 min of vasopressin or 
oxytocin exposure, preceding the addition of the first concentration of [D-Arg8]-inotocin or 
SR49059 was taken as control activity. The activity under each concentration (or time period 
equivalent for vasopressin) were similarly calculated and expressed as a percentage of this control 
period (i.e. control activity is equal to 100%). Values represent the mean ± SEM where ‘n’ is the 
number of samples, each representing a different woman. All methods were performed in 
accordance with the relevant guidelines and regulations. 
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TABLES 
 
Table 1. Affinity (Ki in nM) of inotocin, [D-Arg8]-inotocin and vasopressin on insect and 
human receptors 
Peptide Sequence 
inotocin R 
(L. niger)  
inotocin R  
(T. castaneum) 
human V1aR 
 
human V1bR 
 
human V2R 
 
human OTR 
 
inotocin CLITNCPRG* 6.0 ± 2.8 11 ± 3.9 11 ± 4.4 12 ± 6.5 >105 62 ± 37 
vasopressin CYFQNCPRG* >105 >105 2.6 ± 0.2 1.2 ± 0.6 4.2 ± 1.3 1.8 ± 0.5† 
[D-Arg8]-
inotocin 
CLITNCPrG* 61 ± 10# 217 ± 77 1.3 ± 0.4 >105 >105 >4000 
*C-terminal amide; †value is for oxytocin at the oxytocin receptor; affinity (Ki) data are indicated as mean ± SEM from at least 3 independent 
experiments (except †n=2); Ki values were calculated from IC50 values according to Cheng and Prusoff65, assuming Kd values of 0.6 nM for V1aR, 0.1 
nM for V1bR, 1.2 nM for V2R and 1.5 nM for OTR. Kd values of inotocin receptors were determined from saturation binding experiments to be 0.9 nM (L. 
niger) and 2.7 nM (T. castaneum). 
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Table 2. Potency (EC50 in nM) of inotocin, [D-Arg8]-inotocin and vasopressin on insect and 
human receptors 
Peptide Sequence 
inotocin R  
(L. niger) 
inotocin R  
(T. castaneum) 
human V1aR human V1bR 
human 
V2R 
human 
OTR 
inotocin CLITNCPRG* 0.022 ± 0.006 0.35 ± 0.05 >105 56 ± 9.7 >1500 >105 
vasopressin CYFQNCPRG* >105 >105 0.13 ± 0.02 0.6 ± 0.07 175 ± 76 41 ± 39 
[D-Arg8]-
inotocin 
CLITNCPrG* 1.2 ± 0.7 12 ± 3.5 >105 >105 164 ± 26 >105 
*C-terminal amide; functional receptor activation (EC50) is indicated as mean ± SEM from at least 3 independent experiments. 
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FIGURES 
 
 
 
Fig. 1. Neuropeptide prepro-hormones of humans and insects. (A) Oxytocin (OT), arginine-
vasopressin (AVP) and inotocin (INT) peptide precursors share a similar structure with signal 
peptide (grey), GKR processing signal (black), neurophysin domain (white) and copeptin (dark 
grey, in the case of vasopressin). (B) Multiple sequence alignment of the precursor sequences of 
the black garden ant (L. niger) and the red flour beetle (T. castaneum) were compared to human 
oxytocin and vasopressin. Alignment was performed with Clustal Omega and homologous regions 
were highlighted in Boxshade representation. The mature peptide domains are coloured in red.
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Fig. 2. Receptor pharmacology of inotocin on inotocin and human oxytocin/vasopressin 
receptors. (A) Concentration-dependent displacement of [3H]-inotocin by inotocin at inotocin 
receptors (INTR) from Lasius niger (●) and Tribolium castaneum (●) (n = 4). (B) Concentration-
dependent accumulation of intracellular IP1 by inotocin at INTR from L. niger (n = 4) and T. 
castaneum (n = 9). (C) Concentration-dependent displacement binding of inotocin on human OTR 
(●), V1aR (●), V1bR (●) and V2R (●) (n = 4). (D) Concentration-dependent accumulation of 
intracellular IP1 by inotocin at human OTR, V1aR, V1bR and V2R (n ≥ 3). Specific binding was 
calculated by subtracting the non-specific from the total and normalised to 100%. A full description 
of radioligand and membrane concentrations is reported in the Methods section. Receptor 
activation was measured by IP1 assays for the Gq-coupled receptors (human OTR, V1aR, V1bR) and 
luciferase reporter assay with specific CRE response element for the Gs-coupled human V2R, as 
described in Methods. Each data point was normalized to percentage of maximal activation, 
detected at the highest endogenous ligand concentration, being inotocin for inotocin receptor, 
vasopressin for human V1aR, V1bR, V2R and oxytocin for human OTR. Data is shown as mean ± 
SEM and fitted by nonlinear regression (sigmoidal, three-parameters, Hill slope of 1).  
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Fig. 3. [D-Arg8]-inotocin is a competitive antagonist at the human V1a receptor. (A) 
Concentration-dependent displacement of [3H]-vasopressin in membrane preparations expressing 
the human V1aR by either [D-Arg8]-inotocin or vasopressin (n = 4). Specific binding was calculated 
by subtraction of non-specific binding from total binding and normalized to the percentage (%) of 
maximal binding. (B) Concentration-response curves of vasopressin at the human V1aR in the 
absence and presence of varying concentrations of [D-Arg8]-inotocin (30, 100, 300 and 1000 nM). 
Fold induction of intracellular IP1 accumulation above baseline was normalized to the number of 
cells. Data were fitted by nonlinear regression (sigmoidal, slope = 1). Affinity constants (Ki) and 
potency (EC50) values for AVP and [D-Arg8]-inotocin are presented in Tables 1 and 2. Schild 
regression analysis of [D-Arg8]-inotocin at the human V1aR is shown as insert. The corresponding 
Schild plot is presented in comparison to a linear curve with a slope of 1.0 and the X-intercept of Ki 
for [D-Arg8]-inotocin. The pA2 value of 7.8 was derived as X-intercept of the Schild regression 
curve.  
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Fig. 4. The selectivity of [D-Arg8]-inotocin for V1aR is conferred by a unique binding mode. 
(A) Sequence alignment of the binding site residues of the six investigated receptors, inotocin 
receptors L. niger and T. castaneum, as well as human V1aR, V1bR, V2R and OTR as defined by 
the receptor homology models. Together with the consensus sequence, the conservation score 
from 1 – 10 by physico-chemical properties72 and “∗” indicating complete identity is given below the 
alignment. The sequence-based residue numbers are according to the V1aR, while the numbers in 
parenthesis are generic residue numbers from the GPCR database, GPCRdb.org33. (B and C) 
Models of the inotocin/[D-Arg8]inotocin Arg8/D-Arg8 salt bridge interactions with the receptor 
residues Glu1x35 and Asp45x49, respectively. V1aR is represented as cyan cartoon and sticks, 
Arg8 and D-Arg8 are represented as thick and thin white sticks, respectively, and residues from 
V1bR are shown as magenta sticks. Putative salt-bridge interactions are indicated by the dashed 
lines; green between Arg8 and V1aR, yellow between D-Arg8 and V1aR and red to Arg 175 in 
V1bR37.  
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Fig. 5. Uterine concentration-dependent inhibitory effects of [D-Arg8]-inotocin. Inhibitory 
effect of increasing concentrations of (A) [D-Arg8]-inotocin ([D-Arg8]INT) and (B) the commercially-
available V1aR antagonist SR49059 on vasopressin-augmented (0.5 nM) myometrial contractions. 
Contraction amplitude and area-under-the-curve (AUC) under [D-Arg8]-inotocin treatment (100 nM) 
were significantly reduced (P<0.05 and P<0.001, respectively) as compared to control activity. As 
expected, SR49059 reduced both amplitude of contraction and AUC significantly at 100 nM 
(P<0.001). The mean amplitude of contraction and AUC calculated for 100 nM [D-Arg8]-inotocin, 
SR 49059 or vasopressin (time-equivalent), expressed as a percentage of control where control 
equals 100% are shown in C and D. Application of 100 nM [D-Arg8]-inotocin significantly reduced 
contraction amplitude by 22.9 (±2.5%, P<0.001) and AUC by 36.6 (±13.1%, P<0.05). SR49059 
(100 nM) significantly reduced contraction amplitude and AUC by 54.8 (±15.5%, P<0.001) and 
72.1 (±12.5%, P<0.001), respectively. Contractions augmented by vasopressin (AVP) persisted 
without significant loss of amplitude or AUC for over 2 h during the time equivalent of experimental 
manoeuvers (C-F) and [D-Arg8]-inotocin has no inhibitory effect on contractions augmented with 
oxytocin (G). *P<0.05, **P<0.01, ***P<0.001 (n = 5, one-way ANOVA, Tukey’s post hoc analysis).
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Fig. 6. Putative structure and sequence homology of conserved core triad. (A) Putative 
hydrogen bonding network (yellow dotted lines) of residues in position 3x40, 5x50 and 6x44 of 
V1bR (white cartoon and sticks) in an active receptor state by in silico amino acid exchange into the 
active state µ-opioid receptor crystal structure (PDB code: 5CM1)45. The hydrogen bond between 
Tyr6x44 and the backbone carbonyl of position 5x461 is accomplished by a large movement of 
TM6 relative to the inactive state. (B) Hydrogen bond between Thr3x40 and Tyr6x44 in the inactive 
state V1bR homology model. (C) Sequence conservation of positions 3x40, 5x50 and 6x44 in the 
studied receptors and vasopressin/oxytocin receptors from selected species. Interestingly, most 
V1aRs lack the hydrogen bonding ability in position 3x40 as do the OTRs in position 6x44, which 
according to our model results in different activation kinetics and thus different pharmacology. 
Together with the consensus sequence, the conservation score from 1 – 10 by physico-chemical 
properties72 and “∗” indicating complete identity is given below the alignment.  
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